Pharmaceutical Technology

DECEMBER 14, 2022

GSK has entered a strategic partnership with Wave Life Sciences to progress the discovery and development of oligonucleotide therapies for new genetic targets. The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics. By Cytiva Thematic.

Life Science 162

Life Science Development Gene Therapy Genetics 162

FDA Law Blog

NOVEMBER 2, 2023

While on the surface this may not seem like major advance for the field, this could be a game changer for the gene therapy space. These meetings have a question-and-answer format to provide clarity to sponsors about the particular topics at hand.

Medicine 59

Medicine Gene Therapy Gene Production 59

Drug Discovery World

OCTOBER 16, 2023

Dr Salako says there are some clear fields of work associated with different areas, which include: Hertfordshire as a cell and gene therapy hub, with a number of companies in this space clustered around Stevenage. This includes support for export and expansion into new territories as well as for innovation and development.

Drugs 75

Drugs Life Science Gene Therapy Genome 75

Drug Discovery World

MAY 6, 2024

A more established Amsterdam-based enterprise is gene therapy company uniQure, developer of etranacogene dezaparvovec, the first gene therapy for haemophilia B, which was approved for use in the US in November 2022 and in the EU in February 2023. The CDD will sponsor and manage KWF-supported trials.

Drugs 59

Drugs Life Science Gene Editing Gene 59

Drug Discovery World

OCTOBER 4, 2022

This year’s event will cover some of the most exciting advancements in areas spanning screening, automation, high content imaging, disease models, cell and gene therapies and how innovation is being driven through partnerships and collaborations. Cell and gene therapies. billion, compared to $19.9

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

pharmaphorum

OCTOBER 13, 2022

million in future payments tied to preclinical, clinical development, and commercial achievements. At the end of last year, the company partnered with Atara on mesothelin-targeted CAR-T cell therapies for solid tumours. Bayer bought Vividion for $1.5 Vividion is making an upfront payment of $17.5

Gene Therapy 64

Gene Therapy Genome Genomics Drugs 64

XTalks

OCTOBER 20, 2023

Clinical-stage genome editing company Intellia Therapeutics has received clearance from the US Food and Drug Administration (FDA) for its Investigational New Drug (IND) application to start a pivotal phase III trial of NTLA-2001 for the treatment of transthyretin (ATTR) amyloidosis with cardiomyopathy.

In-Vivo 52

In-Vivo Gene Editing Trials Gene 52

The Pharma Data

DECEMBER 13, 2020

which develops genome editing technologies to accelerate drug discovery and develop novel therapeutics for a broad range of diseases, today announced the appointment of Bo Zhang, Ph.D., as Head of Business Development. 14, 2020 10:00 UTC. BEIJING & CAMBRIDGE, Mass.–( –( BUSINESS WIRE )– EdiGene, Inc.

Business Development 40

Business Development Development Gene Editing In-Vivo 40

Drug Discovery World

SEPTEMBER 14, 2023

joined Pfizer’s Executive Leadership Team as Chief Oncology Research and Development Officer and Executive Vice President reporting to Chairman and Chief Executive Officer, Albert Bourla. Chris Boshoff, M.D.,

Drugs 59

Drugs Vaccination Vaccine Medicine 59

pharmaphorum

SEPTEMBER 12, 2022

Alongside drugs and therapeutics, data collection and technology enhancements have redefined the traditional healthcare experience, especially within oncology, and genomic profiling has become a significant factor in allowing for personalised care. Tailored oncology.

Genome 105

Genome Genomics Clinical Trials Clinical Trials 105

Pharma Marketing Network

DECEMBER 21, 2020

Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e., those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies.

Genetics 52

Genetics Medicine Gene Therapy Marketing 52

pharmaphorum

NOVEMBER 12, 2020

UCB has made a new foray into the gene therapy space, buying fellow Belgium-based company Handl to get control of its adeno-associated virus (AAV) capsid delivery platform and two research programmes in neurodegenerative diseases. The post UCB revs up its gene therapy drive with Handl acquisition appeared first on.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

Delveinsight

SEPTEMBER 14, 2021

Vor Biopharma has declared that the FDA has awarded their acute myeloid leukemia (AML) engineered hematopoietic stem cell therapy (eHSC), VOR33, a Fast Track Designation. VOR33 comprises CRISPR genome-edited hematopoietic stem and progenitor cells , which have been engineered to exclude CD33.

RNA 67

RNA Clinical Trials Clinical Trials Drugs 67

The Pharma Data

NOVEMBER 3, 2020

According to the FDA, the purpose of Fast Track designation is to get important new drugs to patients earlier by facilitating the development, and expediting the review, of drugs to treat serious conditions and fill an unmet medical need. LogicBio is also developing a Next Generation Capsid platform for use in gene editing and gene therapies.

Clinical Trials 52

Clinical Trials Clinical Trials Gene Editing Genome 52

The Pharma Data

NOVEMBER 5, 2020

Velders is presently chairman of HollandBIO, the association of Dutch biotech companies, and provides years of experience, specifically in the cell and gene therapy areas. Taveras will lead all research and non-clinical development functions supporting the company’s pipeline of investigational therapies.

Genome 40

Genome Genomics Medicine Life Science 40

Drug Discovery World

APRIL 29, 2024

Jean-Baptiste Agnus, Chief Business Officer, and Peter Carbone, Chief Quality Officer, KBI Biopharma: Agnus brings more than two decades of experience in the biopharmaceutical industry with expertise in biologics, small molecule APIs, antibody-drug conjugates (ADCs), and cell and gene therapies.

Drugs 52

Drugs Sales Gene Therapy Life Science 52

Pharmaceutical Technology

AUGUST 26, 2008

The dynamic has now changed as many big companies have now acquired biotechnology companies or have developed ‘biotechnology divisions’ of their own. “Big pharmaceutical companies were late adopters of biotechnology based products, continuing to rely on mass screening of new chemical entities,” says Staples.

Antibody 130

Antibody Licensing Licensing Production 130

Drug Discovery World

MAY 30, 2023

FAPi PET is being developed as a highly sensitive imaging agent and can be used as a predictive biomarker for FAP targeted therapeutics, several of which are currently in clinical development. We expect this field to grow significantly in the coming years as these and other earlier stage assets are developed.

Research 52

Research Drugs Protein RNA 52

XTalks

DECEMBER 24, 2020

From isolating SARS-CoV-2 in early January to sequencing its genome shortly thereafter and having a prototype vaccine against it within days, scientific process and progress have held steadfast throughout the pandemic. Infectious disease expert, epidemiologist and director of the Yale Institute for Global Health at Yale University, Saad B.

Life Science 111

Life Science Vaccination Vaccine Gene 111

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52

The Pharma Data

AUGUST 11, 2020

In the field of immune cell therapy, this includes registrational CAR T cell agents for numerous diseases, and a growing early-stage pipeline that expands cell and gene therapy targets, and technologies. To date, the Opdivo clinical development program has treated more than 35,000 patients.

Trials 52

Trials Hormones Clinical Trials Clinical Trials 52